Cryptosporidium parvum oocysts (ABO809)

Phase 2Biologic

Cryptosporidium parvum oocysts (ABO809) is one of 7 biologic programs targeting Cryptosporidiosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CryptosporidiosisRecruiting

CryptosporidiosisPhase 2

Recruiting

Competition

Competitive Landscape

6 competitors in Cryptosporidiosis

#DrugCompanyPhaseTrials

Alinia

RRomark Laboratories L.C.

Phase 3

3 2

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

3 3

EDI048

Novartis

Phase 2

1 4

Cryptosporidium parvum oocysts (ABO809)

Novartis

Phase 2

1 5

Diclazuril

Johnson & Johnson

Preclinical

2 6

Spiramycin

RRhone-Poulenc Rorer

Preclinical

1 7

Interleukin-12

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Cryptosporidiosis

NCT07249463

Clinical

Trials by Indication[1]

Efficacy and Safety1 trial

Study of Efficacy and Safety of ABO809 in Healthy Participants

Completed· Novartis logo

Novartis·Phase 1·NCT05036668·30 enrolled

Cryptosporidiosis1 trial

A Randomized, Placebo-controlled, Participant- and Investigator-blinded Study to Assess the Efficacy and Safety and Tolerability of EDI048 in a Cryptosporidium Controlled Human Infection Model (CHIM) in Healthy Participants

Recruiting· Novartis logo

Novartis·Phase 2·NCT07249463·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Cryptosporidium parvum oocysts (ABO809). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cryptosporidium parvum oocysts (ABO809) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cryptosporidium parvum oocysts (ABO809). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Novartis

Cryptosporidium parvum oocysts (ABO809)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Efficacy and Safety1 trial

Cryptosporidiosis1 trial

References

Drug Info

Quick Facts

Related News